Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05888233 · ClinicalTrials.gov registry record · Phase 2
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
A Phase 2 study of Resistant Hypertension and Heart Failure Preserved Ejection Fraction, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05888233 is a Phase 2 study of Resistant Hypertension and Heart Failure Preserved Ejection Fraction that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 50 participants, below the 3,403-participant average among 4 other Resistant Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05888233, a Phase 2 study of Resistant Hypertension and Heart Failure Preserved Ejection Fraction, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
African American adults in the United States have the highest prevalence rate of high blood pressure (hypertension) and heart failure in the world. African Americans with treatment resistant hypertension have higher levels of the enzyme - xanthine oxidase compared to Caucasians. This trial will test if administration of the xanthine oxidase inhibitor - Allopurinol (commonly used in the treatment of gout), given over a period of 8 weeks, will improve heart function, exercise ability and quality of life in African American Veterans with resistant hypertension.
Conditions Studied
Interventions
- DRUG Allopurinol
Study Locations (1)
Alabama
- Birmingham VA Medical Center, Birmingham, AL - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05888233
The ClinicalTrials.gov registry entry for NCT05888233 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,403-participant average among 4 other Resistant Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Resistant Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Allopurinol is the first listed.
NCT05888233 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT05888233 about?
NCT05888233 is a clinical study titled "Allopurinol Improves Heart Function in African Americans With Resistant Hypertension". African American adults in the United States have the highest prevalence rate of high blood pressure (hypertension) and heart failure in the world. African Americans with treatment resistant hypertension have higher levels of the enzyme - xanthine oxidase compared to Caucasians. This trial will test...
What is the current status of trial NCT05888233?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-09-30. Estimated completion is 2026-05-31.
What conditions does trial NCT05888233 study?
This clinical trial studies the following conditions: Resistant Hypertension, Heart Failure Preserved Ejection Fraction.
What interventions are being tested in trial NCT05888233?
The interventions under investigation include: Allopurinol (DRUG).
Who is sponsoring clinical trial NCT05888233?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05888233 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Resistant Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
RECRUITING · NA
-
CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™
ACTIVE NOT RECRUITING · NA
-
Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension
ACTIVE NOT RECRUITING · NA
-
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
COMPLETED · Phase 3
Explore more on PlainTrial
Resistant Hypertension
All registered trials for this condition
Heart Failure Preserved Ejection Fraction
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.